TABLE 3.

Multivariable survival analysis of the association between CRE BSI and (A) all-cause mortality, (B) new-onset graft failure

A. All-cause mortality
Characteristic	aHR	95% CI	P
CRE BSI (compared to non-CRE EB BSI)	2.85	1.68-4.84	<0.001
Prior CRE colonization/infectiona	0.90	0.45-1.77	0.749
Age (per y)	1.03	1.01-1.05	<0.001
Prior EB on respiratory culturea	3.08	2.00-4.74	<0.001
Prior exposure to a polymyxinb	2.51	1.32-4.79	0.005
Rejection before the EB BSI, treated with corticosteroidsc	1.91	1.05-3.47	0.034
Graft failure before the EB BSI	1.90	1.30-2.77	0.001
Organ transplant type
Kidney	Ref
Liver	2.68	1.72-4.19	<0.001
Heart	1.22	0.54-2.77	0.631
Lung	1.45	0.73-2.89	0.293
Pancreas	3.79	1.46-9.82	0.006
B. New-onset graft failure
Characteristic	aSHR	95% CI	P
CRE BSI (compared to non-CRE EB BSI)	2.42	1.33-4.39	0.004
Rejection before the EB BSIc	1.86	1.03-3.36	0.040
Prior EB on genitourinary culturea	0.43	0.23-0.81	0.009
Prior EB on respiratory culturea	2.53	1.31-4.87	0.006
Prior exposure to metronidazoleb	1.77	1.05-2.96	0.030
Prior exposure to an aminoglycosideb	0.90	0.46-1.80	0.756
Organ transplant type
Kidney	Ref
Liver	2.00	1.10-3.65	0.024
Heart	1.41	0.53-3.71	0.491
Lung	1.47	0.59-3.64	0.408
Pancreas	3.49	1.40-8.69	0.007
Study site
Site 1	Ref
Site 2	0.59	0.35-1.02	0.059
Site 3	0.47	0.28-0.80	0.005

^aOrganism isolated on any clinical culture from any anatomical site in the 12 mo before the EB BSI. (No surveillance cultures performed at the included study sites.)

^bExposure within the 6 mo before the EB BSI.

^cRejection within the 3 mo before the EB BSI.

aHR, adjusted hazard ratio; aSHR, adjusted subhazard ratio; BSI, bloodstream infection; CI, confidence interval; CRE, carbapenem-resistant EB; EB, Enterobacterales; ref, reference.